Coty Class Action Lawsuit Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 25 2026
0mins
Should l Buy COTY?
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Coty Inc. (NYSE: COTY) common stock between November 5, 2025, and February 4, 2026, to apply as lead plaintiffs by May 22, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Coty made false and misleading statements during the class period, concealing the true state of its slowing growth in the beauty market, particularly the underperformance in the Consumer Beauty segment, which led to investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong capabilities and successful track record in this field.
- Participation Instructions: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, with no upfront fees required for participating investors, ensuring broad access to the class action.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COTY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COTY
Wall Street analysts forecast COTY stock price to rise
12 Analyst Rating
1 Buy
9 Hold
2 Sell
Hold
Current: 2.650
Low
2.50
Averages
4.30
High
10.00
Current: 2.650
Low
2.50
Averages
4.30
High
10.00
About COTY
Coty Inc. is a beauty company with a portfolio of brands across fragrance, color cosmetics, and skin and body care. The Company has a diverse portfolio of brands, which includes both owned and licensed. Its brand portfolio is classified into two segments: Consumer beauty and Prestige. The consumer beauty brands include Adidas, Beckham, Bozzano, Bourjois, Bruno Banani, CoverGirl, Jovan, Mexx, LeGer by Lena Gercke, Monange, Nautica, Paixao, Rimmel, Risque, Sally Hansen, and Vera Wang. Its prestige brands include Burberry, Calvin Klein, Chloe, Davidoff, Escada, Gucci, Hugo Boss, Jil Sander, Kylie Cosmetics by Kylie Jenner, Lancaster, Marc Jacobs, Miu Miu, Orveda, and Tiffany & Co. Its mass beauty brands are primarily sold through hypermarkets, supermarkets, drug stores and pharmacies, mid-tier department stores, traditional food and drug retailers, and dedicated e-commerce retailers. It markets, sells and distributes its products in over 120 countries and territories.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Coty Q3 Earnings Call: Market Challenges and Strategic Adjustments
- Sales Gap: Coty's Executive Chairman Markus Strobel highlighted a persistent gap between Prestige sell-out and sell-in, primarily driven by disruptions in the Middle East, which rendered sales nearly impossible in March, indicating vulnerability in that region's market and potential impacts on future revenue growth.
- Consumer Beauty Trends: While unit sales improved in key U.S. brands, lower sell-in figures resulted from a shift away from large bundles and exits from select markets, underscoring the challenges Coty faces in market competition and the necessity for strategic adjustments.
- Oil Price Sensitivity: CFO Laurent Mercier quantified that a $1 increase in oil prices would reduce profits by $2 million, illustrating the pressure on Coty regarding cost control and procurement strategies, with mitigation expected through hedging policies by the end of 2026.
- Future Profitability Goals: Management set a goal for improving profitability in fiscal 2027 without providing specific targets, emphasizing that growth will be achieved through innovation and enhanced consumer engagement, reflecting the company's confidence and strategic direction for the future.
See More
Coty Class Action Lawsuit Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Coty Inc. (NYSE: COTY) common stock between November 5, 2025, and February 4, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action, as those who do not will not be represented by counsel.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, allowing investors to seek compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that Coty made false and misleading statements during the class period, concealing the true state of its slowing growth in the beauty market, which led to investor losses when the truth emerged, highlighting underperformance in the consumer beauty sector.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its extensive experience and success in handling such cases.
See More
Multiple Companies Face Class Action Lawsuits
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics faces a class action lawsuit for the period from May 20, 2024, to January 9, 2026, alleging undisclosed manufacturing issues and clinical trial risks that overstated FDA approval prospects, potentially leading to significant negative impacts on the company's financial condition.
- Coty Performance Decline: Coty Inc. is under scrutiny in a class action lawsuit covering November 5, 2025, to February 4, 2026, with claims that its Consumer Beauty segment underperformed, increased marketing investments compressed margins, and slowing growth in the Prestige fragrance market rendered the company's positive statements misleading.
- Super Micro Sales Violations: Super Micro Computer is implicated in a class action lawsuit for the period from February 2, 2024, to March 19, 2026, alleging that a significant portion of its server sales to Chinese companies violated U.S. export control laws, with material weaknesses in compliance controls leading to misleading positive statements about the company's operations.
- ImmunityBio Capability Overstatement: ImmunityBio faces a class action lawsuit for the period from January 19, 2026, to March 24, 2026, alleging that executive Soon-Shiong materially overstated Anktiva's capabilities, resulting in misleading positive statements about the company's business and operations, which could undermine investor confidence.
See More
Coty Executives Face Securities Class Action Lawsuit
- Significant Stock Decline: Coty's shares plummeted from $3.43 to $2.66, a loss of $0.77 (22%), primarily due to the company's withdrawal of its $1 billion adjusted EBITDA target and admission of widespread operational failures, severely undermining investor confidence.
- Executive Liability Allegations: CEO Sue Nabi and CFO Laurent Mercier are named as individual defendants, facing accusations of being controlling persons responsible for the company's operational failures, which raises serious concerns about corporate governance and accountability.
- Legal Framework Basis: Under Section 20(a) of the Securities Exchange Act of 1934, controlling individuals may be held liable for securities law violations, with the lawsuit asserting that both executives failed to ensure the accuracy of disclosures during their tenure, potentially leading to severe repercussions.
- Internal Data Misrepresentation: The lawsuit claims that both executives, while certifying SEC filings, were aware of significant discrepancies between internal data and the positive growth narrative presented to investors, indicating possible willful or reckless disregard for shareholder interests.
See More
Investor Class Action Lawsuit Reminder
- Lufax Lawsuit Details: Lufax Holding Ltd. (NYSE:LU) is facing a class action lawsuit for failing to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, with a lead plaintiff deadline of May 20, 2026, which could adversely affect the company's reputation and stock price.
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is being sued for undisclosed manufacturing issues and clinical trial risks during the class period from May 20, 2024, to January 9, 2026, requiring lead plaintiff motions by May 22, 2026, potentially jeopardizing future FDA approvals and impacting the company's financial outlook.
- Coty Lawsuit Overview: Coty Inc. (NYSE:COTY) faces a class action lawsuit for underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, with a lead plaintiff deadline of May 22, 2026, which may lead to significant financial repercussions for the company.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors who suffered losses during the specified periods to contact them for legal advice to protect their rights and mitigate potential financial losses.
See More
Coty Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Coty in the Southern District of New York on behalf of investors who purchased shares between November 5, 2025, and February 4, 2026, indicating significant investor dissatisfaction with the company's performance.
- Allegations of Misrepresentation: The lawsuit alleges that Coty made false and/or misleading statements during the class period, concealing the true state of its slowing growth in the beauty market, particularly the underperformance in the Consumer Beauty segment, resulting in investor losses.
- Investor Rights Protection: Investors must apply by May 22, 2026, to be appointed as lead plaintiff, highlighting the importance of this case for protecting investor rights and its potential impact on Coty's future stock performance.
- Legal Consultation Availability: Bragar Eagel & Squire offers free consultations for affected investors, who can reach out via phone or email, demonstrating the firm's commitment to supporting investor rights and interests.
See More
Coty Q3 Earnings Call: Market Challenges and Strategic Adjustments
- Sales Gap: Coty's Executive Chairman Markus Strobel highlighted a persistent gap between Prestige sell-out and sell-in, primarily driven by disruptions in the Middle East, which rendered sales nearly impossible in March, indicating vulnerability in that region's market and potential impacts on future revenue growth.
- Consumer Beauty Trends: While unit sales improved in key U.S. brands, lower sell-in figures resulted from a shift away from large bundles and exits from select markets, underscoring the challenges Coty faces in market competition and the necessity for strategic adjustments.
- Oil Price Sensitivity: CFO Laurent Mercier quantified that a $1 increase in oil prices would reduce profits by $2 million, illustrating the pressure on Coty regarding cost control and procurement strategies, with mitigation expected through hedging policies by the end of 2026.
- Future Profitability Goals: Management set a goal for improving profitability in fiscal 2027 without providing specific targets, emphasizing that growth will be achieved through innovation and enhanced consumer engagement, reflecting the company's confidence and strategic direction for the future.
See More
Coty Class Action Lawsuit Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Coty Inc. (NYSE: COTY) common stock between November 5, 2025, and February 4, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action, as those who do not will not be represented by counsel.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, allowing investors to seek compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that Coty made false and misleading statements during the class period, concealing the true state of its slowing growth in the beauty market, which led to investor losses when the truth emerged, highlighting underperformance in the consumer beauty sector.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its extensive experience and success in handling such cases.
See More
Multiple Companies Face Class Action Lawsuits
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics faces a class action lawsuit for the period from May 20, 2024, to January 9, 2026, alleging undisclosed manufacturing issues and clinical trial risks that overstated FDA approval prospects, potentially leading to significant negative impacts on the company's financial condition.
- Coty Performance Decline: Coty Inc. is under scrutiny in a class action lawsuit covering November 5, 2025, to February 4, 2026, with claims that its Consumer Beauty segment underperformed, increased marketing investments compressed margins, and slowing growth in the Prestige fragrance market rendered the company's positive statements misleading.
- Super Micro Sales Violations: Super Micro Computer is implicated in a class action lawsuit for the period from February 2, 2024, to March 19, 2026, alleging that a significant portion of its server sales to Chinese companies violated U.S. export control laws, with material weaknesses in compliance controls leading to misleading positive statements about the company's operations.
- ImmunityBio Capability Overstatement: ImmunityBio faces a class action lawsuit for the period from January 19, 2026, to March 24, 2026, alleging that executive Soon-Shiong materially overstated Anktiva's capabilities, resulting in misleading positive statements about the company's business and operations, which could undermine investor confidence.
See More
Coty Executives Face Securities Class Action Lawsuit
- Significant Stock Decline: Coty's shares plummeted from $3.43 to $2.66, a loss of $0.77 (22%), primarily due to the company's withdrawal of its $1 billion adjusted EBITDA target and admission of widespread operational failures, severely undermining investor confidence.
- Executive Liability Allegations: CEO Sue Nabi and CFO Laurent Mercier are named as individual defendants, facing accusations of being controlling persons responsible for the company's operational failures, which raises serious concerns about corporate governance and accountability.
- Legal Framework Basis: Under Section 20(a) of the Securities Exchange Act of 1934, controlling individuals may be held liable for securities law violations, with the lawsuit asserting that both executives failed to ensure the accuracy of disclosures during their tenure, potentially leading to severe repercussions.
- Internal Data Misrepresentation: The lawsuit claims that both executives, while certifying SEC filings, were aware of significant discrepancies between internal data and the positive growth narrative presented to investors, indicating possible willful or reckless disregard for shareholder interests.
See More
Investor Class Action Lawsuit Reminder
- Lufax Lawsuit Details: Lufax Holding Ltd. (NYSE:LU) is facing a class action lawsuit for failing to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, with a lead plaintiff deadline of May 20, 2026, which could adversely affect the company's reputation and stock price.
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is being sued for undisclosed manufacturing issues and clinical trial risks during the class period from May 20, 2024, to January 9, 2026, requiring lead plaintiff motions by May 22, 2026, potentially jeopardizing future FDA approvals and impacting the company's financial outlook.
- Coty Lawsuit Overview: Coty Inc. (NYSE:COTY) faces a class action lawsuit for underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, with a lead plaintiff deadline of May 22, 2026, which may lead to significant financial repercussions for the company.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors who suffered losses during the specified periods to contact them for legal advice to protect their rights and mitigate potential financial losses.
See More
Coty Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Coty in the Southern District of New York on behalf of investors who purchased shares between November 5, 2025, and February 4, 2026, indicating significant investor dissatisfaction with the company's performance.
- Allegations of Misrepresentation: The lawsuit alleges that Coty made false and/or misleading statements during the class period, concealing the true state of its slowing growth in the beauty market, particularly the underperformance in the Consumer Beauty segment, resulting in investor losses.
- Investor Rights Protection: Investors must apply by May 22, 2026, to be appointed as lead plaintiff, highlighting the importance of this case for protecting investor rights and its potential impact on Coty's future stock performance.
- Legal Consultation Availability: Bragar Eagel & Squire offers free consultations for affected investors, who can reach out via phone or email, demonstrating the firm's commitment to supporting investor rights and interests.
See More
